Background: Kinetin is a plant hormone that regulates growth and differentiation. Keratinocytes, the basic building blocks of the epidermis, function in maintaining the skin barrier. Objective: We examined whether kinetin induces skin barrier functions in vitro and in vivo. Methods: To evaluate the efficacy of kinetin at the cellular level, expression of keratinocyte differentiation markers was assessed. Moreover, we examined the clinical efficacy of kinetin by evaluating skin moisture, transepidermal water loss (TEWL), and skin surface roughness in patients who used kinetin-containing cream. We performed quantitative real-time polymerase chain reaction to measure the expression of keratinocyte differentiation markers in HaCaT cells following treatment. A clinical trial was performed to assess skin moisture, TEWL, and evenness of skin texture in subjects who used kinetin-containing cream for 4 weeks. Results: Kinetin increased involucrin, and keratin 1 mRNA in HaCaT cells. Moreover, use of a kinetin-containing cream improved skin moisture and TEWL while decreasing roughness of skin texture. Conclusion: Kinetin induced the expression of keratinocyte differentiation markers, suggesting that it may affect differentiation to improve skin moisture content, TEWL, and other signs of skin aging. Therefore, kinetin is a potential new component for use in cosmetics as an anti-aging agent that improves the barrier function of skin. (Ann Dermatol 29(1) 6∼
INTRODUCTION
The effects of human aging are mostly visible in the skin in such forms as increased wrinkling and sagging, as well as decreased elasticity 1 . Aging is also associated with physical disorders of the skin because its barrier function is disrupted, leading to a dry appearance and enhanced risk of skin disorders 2, 3 . Understanding the mechanisms of skin aging is important for developing skin care products that delay aging and reduce damage 4, 5 . Skin aging is induced by both intrinsic and extrinsic factors 4, 6 that lead to a reduction of structural integrity and loss of physiological function 6 . Kinetin, a cytokine isolated in 1955, is an essential plant growth hormone that regulates cell growth and differentiation 7, 8 . Kinetin has also been reported to be present in human cell extracts 9 and urine 10 , and has been identified as a naturally occurring base modification agent of DNA 11 . Kinetin has been reported to have multiple functions, including anti-aging effects in cultured cells 12, 13 and fruit flies 14 , antioxidant properties 15, 16 , antithrombotic activity 17, 18 , and cell differentiation effects [19] [20] [21] . Therefore, in
this study, we demonstrate that kinetin may induce anti-aging effects in skin by improving its barrier function.
MATERIALS AND METHODS

Cell culture
HaCaT human keratinocytes (American Type Culture Collection, Boulecard Manassas, VA, USA) were cultured in Dulbecco's modified Eagle medium (Gibco/Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Sigma-Aldrich, St. Louis, MO, USA) and 1% penicillin/streptomycin (Gibco/Life Technologies) at 37 o C in an atmosphere of 5% CO2. Kinetin was purchased from Sigma-Aldrich and dissolved in dimethyl sulfoxide.
Cell viability assay
HaCaT cells were seeded at a density of 3×10 3 cells in 96-well plates and incubated for 24 h. The cells were then incubated with kinetin (0∼600 μM) for 24 h. HaCaT cell toxicity due to kinetin was evaluated using a water-soluble tetrazolium salt (WST)-1 assay (EZ-Cytox Cell Viability Assay Kit; Itsbio, Seoul, Korea). WST-1 solution was added to cultured cells at a volume equal to 10% that of the culture medium, and then the cells were incubated at 37 o C for 1 h. Cell viability was evaluated by measuring the absorbance at 450 nm using an iMark microplate reader (Bio-Rad, Hercules, CA, USA).
Isolation of total RNA and quantitative real-time polymerase chain reaction Total RNA was isolated using TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer's protocol. The purity and concentration of the RNA were evaluated using a MaestroNano Ⓡ , a microvolume spectrophotometer (Maestrogen, Las Vegas, NV, USA). The recommended parameters of RNA quality for cDNA synthesis were OD 260/230 ＞1.8 and an OD 260/280 ratio within the range of 1.8∼2.0. cDNAs were synthesized using the miScript II RT Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. To evaluate the expression of INV (forward primer: 5'-GGGTGGTTATTTATGTTTGGGTGG-3', reverse primer: 5'-GCCAGGTCCAAGACATTCAAC-3') and KRT1 (forward primer: 5'-ATTTCTGAGCTGAATCGTGTGATC-3', reverse primer: 5'-CTTGGCATCCTTGAGGGCATT-3'), quantitative real-time polymerase chain reaction was performed using EvaGreen dye (Solis BioDyne, Tartu, Estonia) with Line-Gene K software (Bioer Technology Co., Ltd., Hangzhou, China). The CT value for each gene was normalized to β-actin (forward primer: 5'-GGATTCCTATGTGGGCGACGA-3', reverse primer: 5'-CGCTCGGTGAGGATCTTCATG-3'). Relative expression levels of each gene were calculated using the 2 −ΔΔ Ct method 22 .
Subjects for clinical evaluation
The study protocols were approved by the Institutional Review Board of KISCS Incorporated (Cheongju, Korea) (IRB no. 1-70005239-A-N-01-2013-KISCS-ACA001-KSH). All subjects were informed about the objective of the study and provided informed consent and agreed to use products for skin care during the study. Forty women greater than 40 years of age were enrolled in a randomized, double-blind clinical trial (control group: 46.80± 4.83 years, experiment group: 46.70±0.83 years). The subjects were selected based on age, the absence of skin conditions other than age-related conditions, and were not pregnant or nursing. All subjects were informed about the objective of the study, provided signed informed consent, and agreed to use only products for skin care during the study. Reasons for dropping out were itching, erythema, or excessive drinking or smoking. Subjects were divided into control and experimental groups consisting of 20 subjects each. All conditions were identical, other than the exposure of the experimental group to the test material. The study lasted four weeks, except no drop out. Clinical parameters were evaluated three times, namely, before application, and after 2 and 4 weeks of use. The investigator asked subjects about the condition of their skin and performed a visual examination of their skin condition, such as erythema, itching, scale, edema, tingling, and burning sensation, at every visit. The cream was prepared by incorporating the ingredients in the three phases (A, B, C). Ingredients in the A phase (distilled water, glycerin, 1,3-butylene glycol) were combined and heated until all the components were melted, and ingredients in the B phase (distilled water, dipotassium phosphate, sodium hydroxylate, kinetin) were combined and heated to the same temperature, to ensure homogeneity. The A and B phases were combined and emulsified using a homo mixer (Tokushu Kika Kogyo Co., Ltd., Osaka, Japan) at 5,000 rpm for 10 min. The mixture was cooled to 60 o C and blended with the homogenized phase C (emulium delta, sepipuls 400) at 5,000 rpm for 10 min. By then, the temperature of the mixture had dropped to 45 o C. The mixture was combined and homogenized, while maintaining the pH at 6.2. The cream provided to the experimental group contained 2% (wt%) kinetin and the cream provided to the control group was prepared using the same volume of water in place of kinetin.
Experimental procedures
To investigate the improvement in skin barrier function, subjects were instructed to apply 2 g of test material to the face every morning and night for 4 weeks. Subjects and investigators were blinded to test and control treatments. Moisture and transepidermal water loss (TEWL) were measured on the right cheek and skin texture was evaluated on the left side of the forehead. At every visit, before measurements were taken, all subjects washed with the cleanser provided and lay quietly in a room with constant temperature (22 o C±1 o C) and humidity (45%±5%) so that all subjects would be evaluated under the same conditions.
Evaluation of skin moisture
To evaluate improvement in skin moisture, the DermaLab USB moisture probe (Cortex Technology Inc., Hadsund, Denmark) was applied and data were analyzed using the associated application software version 1.09. All subjects were measured on the same region of the right cheek five consecutive times, and the mean, maximum, and minimum values were determined. Measurements were taken three times, namely, before application, and after 2 and 4 weeks of use. The device applies the conductance measurement principle to measure the water-binding capacity of the stratum corneum (SC). This value correlates with skin moisture and is expressed in microsiemens (μS).
TEWL measurements
To evaluate improvement in TEWL, the DermaLab USB TEWL probe (Cortex Technology Inc.) was applied and data were analyzed using the associated application software version 1.09. Five consecutive measurements were taken on the subject's right cheek, and the mean, maximum, and minimum values were determined. Measurements were taken three times, namely, before application and at 2 and 4 weeks after the application.
Measurement of facial skin evenness
Facial skin evenness measured by PRIMOS Lite (field of view 45×30; GFMesstechnik GmbH, Teltow, Germany) was used to obtain clinical images. Captured images were analyzed using the associated imaging software, PRIMOS Lite version 5.6E. Three consecutive clinical images of the left side of the subject's forehead were captured. Facial skin roughness was assessed based on the Ra value, which is the average of all heights and depths relative to the reference plane. Measurements were taken three times, namely, before application, and at 2 and 4 weeks after the application. The Ra value is the most widely used parameter of facial skin roughness and is the arithmetic mean of the maximum values of all measurements.
Statistical and mathematical analysis where A is defined as the individual value of any parameter at the 2 and 4 week visits and B represents the zero hour of the assessed parameter.
RESULTS
Cytotoxicity of kinetin in human keratinocytes
To determine whether kinetin affects HaCaT cell viability, cells were exposed to kinetin at concentrations ranging from 0∼600 μM for 24 h. As shown in Fig. 1 , kinetin reduced cell viability by 8.88% at 200 μM, 18.99% at 400 μM, and 29.78% at 600 μM. Kinetin-induced cytotoxicity increased significantly at concentrations greater than 200 μM. Thus, we used 200 μM as the maximum concentration in subsequent experiments.
Effect of kinetin on expression of keratinocyte differentiation markers
Expression of involucrin, a marker of keratinocyte differentiation, was not altered by the treatment of HaCaT cells with 0.25 mM CaCl2. But when cells were treated with kinetin, involucrin mRNA increased in a dose-dependent manner. The addition of kinetin following treatment with 0.25 mM CaCl2 increased the level of involucrin mRNA to that of cells treated with 2 mM CaCl2 alone (Fig. 2) . Simultaneously, we investigated the gene expression of another keratinocyte differentiation maker, keratin 1. As seen for involucrin, keratin 1 expression was not altered by treatment of HaCaT cells with 0.25 mM CaCl2. However, when these cells were treated with kinetin, keratin 1 expression increased markedly (Fig. 3) .
Kinetin-containing cream improves skin hydration
Keratinocyte moisture content is pivotal for maintaining moisture in the skin. Normal keratinocytes maintain 10% ∼30% moisture; however, when moisture content drops below 10%, keratinocytes are unable to maintain the skin's barrier function as skin becomes dry, acquires an uneven texture, and produces wrinkles, which accelerate senescence 23 . In this study, to evaluate the efficacy of kinetin treatment on skin, we investigated the improvement Fig. 4 . Improvement in skin moisture over time. Measurements were taken three times, namely before application and after 2 and 4 weeks of application. To evaluate improvement in skin moisture, DermaLab USB moisture probe was applied and data were analyzed using the associated software application version 1.09. *p＜0.001 as determined by the Student's t-test. in skin moisture after the treatment with a kinetin-containing cream. We analyzed skin moisture content using the DermaLab USB moisture probe. Our data demonstrate that the moisture content of the control group, which used the non-kinetin-containing cream, was 388.10 μS before use, 389.96 μS after 2 weeks, and 390.72 μS after 4 weeks of application (Fig. 4) . To compare the improvement at 2 and 4 weeks, we calculated and expressed the degree of improvement (Fig. 4) . Consequently, the moisture content of the control group increased by 0.48% and 0.68% after 2 and 4 weeks, respectively. These changes were not statistically significant (p＞0.05), indicating that the non-kinetin-containing cream had no measurable effect on moisture content. In contrast, the moisture content in the experimental group, which used kinetin-containing cream, was 413.34 μS before use, 551.39 μS after 2 weeks, and 619.98 μS after 4 weeks (Fig. 4) . Interestingly, the use of the kinetin-containing cream significantly improved skin moisture by 33.40% and 49.99% after 2 and 4 weeks, respectively (p＜0.001). These experiments demonstrate that the use of the kinetin-containing cream resulted in improved skin moisture content.
Improvement in TEWL following use of kinetincontaining cream
Next, to determine the efficacy of kinetin as a skin moisturizer, we used the DermaLab USB TEWL probe to investigate TEWL in the skin of subjects who had used control or kinetin-containing cream. The TEWL of control subjects was 9.59 g m −2 h −1 before use, 9.48 g m −2 h −1 after 2 weeks, and 9.38 g m −2 h −1 after 4 weeks (Fig. 5) . To compare the improvement at 2 and 4 weeks, we calculated the improvement as a percentage based on the value before application. Consequently, the TEWL in the control group increased by 1.15% and 2.19% after 2 and 4 weeks of use, respectively. These changes were not statistically significant (p＞0.05), indicating that the non-kinetin-containing cream had no measurable effect on TEWL. In contrast, TEWL in the experimental group was 9.96 g m (Fig. 5) . To compare the improvement at 2 and 4 weeks, we calculated the improvement in TEWL as a percentage based on the value before application. Use of the kinetin-containing cream significantly improved TEWL by 10.40% and 28.88% after 2 and 4 weeks, respectively (p＜0.001). Through these experiments, we identified the improvement in TEWL as an outcome of using kinetin-containing cream.
Use of kinetin-containing cream improves evenness of skin texture
The thickness of the SC changes depending on its moisture content. Insufficient moisture in this layer roughens skin texture gradually 24 . Therefore, we investigated the efficacy of kinetin-containing cream on skin texture. Facial skin evenness was measured using PRIMOS Lite. Evenness in the control group was 20.10 Ra before use, 19 .95 Ra after 2 weeks, and 19.79 Ra after 4 weeks (Fig. 6 ). To compare the improvement at 2 and 4 weeks, we calculated the improvement as a percentage based on the value before application. Consequently, skin texture in the control group improved by 0.77% and 1.54%, after 2 and 4 weeks of use, respectively. These data were not statistically sig- (Fig. 6) . To compare the improvement after 2 and 4 weeks, we calculated the improvement as a percentage based on the value before application. Using the kinetin-containing cream significantly improved the evenness of skin texture by 7.39% and 19.54% after 2 and 4 weeks (p＜0.001), respectively. Through these experiments, we revealed that use of kinetin-containing cream can improve skin texture.
Analysis of adverse effects of kinetin-containing cream
In this study, investigators asked the subjects individually about the condition of their skin and performed a visual evaluation of skin reactions, such as erythema, itching, scaling, tingling, tightness, prickling, and burning sensation at every visit. No extraordinary reactions were reported based on either visual evaluation or the questionnaire.
DISCUSSION
Kinetin has been reported to confer antioxidant and anti-aging effects in cultured cells 12, 13, 15, 16 . However, whether kinetin plays a role in the barrier function of the skin remains to be investigated. Kinetin contributes to the delay in the skin aging process 13, 19 . In the present study, we examined whether kinetin reduces the aging process by improving skin barrier function. First, we evaluated the cytotoxicity of kinetin. HaCaT cell viability was affected at kinetin concentrations greater than 200 μM. Thus, 200 μM was used as the maximum concentration in subsequent experiments (Fig. 1 ). Our data demonstrate that the expression of keratinocyte differentiation markers, involucrin and keratin 1, was induced by kinetin in a dose-dependent manner (Fig. 2, 3) . Furthermore, the expression of the major transcription factor p63 was upregulated by kinetin treatment (data not shown). Skin generates epidermal barrier by keratinocyte differentiation, which prevents water loss and maintain moisture 25 .
To evaluate the clinical efficacy of kinetin, we prepared a kinetin-containing cream and tested it on human skin. Because TEWL is used for assessing the epidermal barrier function, we used it as one of the parameters for evaluating the anti-aging effect of kinetin 25 in a randomized, double-blind clinical trial. The control and experimental groups (n=20 each) used non-kinetin-containing and kinetin-containing creams, respectively. The skin moisture content and TEWL improved following the use of the kinetin-containing cream (Fig. 4, 5 ). Taken together, our results indicate that kinetin induced the formation of the skin barrier by accelerating keratinocyte differentiation. Human skin acts as a barrier between the internal and external environment. Therefore, the skin protects the body from mechanical damage, noxious substances, and penetration by pathogens and radiation. The skin also plays a vital role in regulating body homeostasis by reducing TEWL to a minimum via the SC. Dysfunctional keratinocyte differentiation, such as in aging skin, leads to the thinning of the epidermis and destruction of the skin barrier, which can be caused by a reduction in filaggrin, a natural moisturizing factor synthesized by differentiating keratinocytes 26 . In addition, topical application of kinetin reduced spots, pores, and wrinkles, as well as improved the evenness of the skin texture 27 . Evenness of skin texture increased with the use of the kinetin-containing cream in a time-dependent manner (Fig. 6 ). Compared to pre-application roughness, evenness of the skin texture increased by 7.39% after 2 weeks of application and by 19.53% after 4 weeks (Fig. 6) . Moreover, kinetin-containing cream was effective in treating wrinkles around the eye, such as crow's feet or under-eye wrinkles. In fact, using the kinetin-containing cream for 4 weeks reduced the number of under-eye wrinkles and the length and area of crow's feet (data not shown). These data demonstrate the clinical efficacy of kinetin on wrinkle elimination.
In conclusion, we identified a potential new cosmetic component derived from nature. We demonstrate the efficacy of kinetin for moisturizing and reducing the aging effects in both human keratinocytes in vitro and in the clinic. These findings indicate that kinetin reversed the effects of skin aging by modulating the skin barrier functions, suggesting that kinetin is a potentially useful component for various cosmetic uses.
